Products

LearnObit (Beta 2)

A cognitive tool to boost learning

learnobit.com Education / Study Tools

AI Benchmark
Monthly visits
<5K
Oct 2026
Public revenue
Undisclosed
No public revenue evidence yet
Entry price
Unknown
No monthly subscription pricing
Creators
Sungho Yahng
No social account linked
Launched
6y ago
2020-02-12 · Est.

Traffic

Monthly visitsData through Oct 2026

Marketing moves

Launches, search & content, referrals, promotions
  • Launched on Product HuntLaunch

    A cognitive tool to boost learning

    Mar 3, 2021 · 5y agoLaunch page

  • Launched on Show HN (23 pts · 20 comments)Launch

    A Tool for Rapid Learning Process (It's like Anki + Workflowy)

    Feb 21, 2020 · 6y agoLaunch page

  • Launched on BetaListLaunch

    LearnObit – A Tool for Rapid Learning Process, it's like Anki + workflowy — A Tool for Rapid Learning Process, it's like Anki + workflowy

    Feb 12, 2020 · 6y agoLaunch page

Traffic sources

Oct 2026

Traffic breakdown

Channels

No data yet

Countries

No data yet

Search

Domain authority —Domain registered 2026-02-05

No search keyword data for this website yet.

Traffic data: Vaneform

Pricing

Pricing page not identified yet, or no public pricing listed.

Pages & changes

Tracked since 2021-03-03

Key pages

Weekly snapshots

No page snapshots yet. Once followed, home and pricing pages are captured weekly.

Changes

No pricing, plan, or positioning changes detected since tracking started.

Questions & evidence

How much website traffic does LearnObit (Beta 2) get?
Vaneform estimates <5K website visits in 2026-10. Visits can include repeat visits; this estimate measures web traffic separately from paying customers or revenue.Source
What is LearnObit (Beta 2) and what platforms does it support?
LearnObit (Beta 2) is catalogued under Study Tools: A cognitive tool to boost learning. Supported platforms: Web.

Related products in this category

Education / Study Tools

These products share a catalog category. Compare customer tasks, features and deployment requirements before treating them as alternatives.